hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases
Category: #health  By Pankaj Singh  Date: 2019-08-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases

This clinical study will assess the safety and immunogenicity of vaccine when given with or without adjuvant to small cohorts of healthy subjects.

hVIVO plc has reportedly announced that AGS-v PLUS, an investigational vaccine created to protect against several different mosquito-borne diseases, will be examined in a phase 1 clinical trial. The phase 1 trial will be conducted by the NIH at the University of Maryland School of Medicine. AGS-v PLUS vaccine was developed by Imutex Limited which is 49 percent joint venture of hVIVO with the SEEK Group. The study has received additional funding from the UK Department of Health and Social Care which is managed by Innovate UK.

Apparently, AGS-v PLUS has been created to activate an immune reaction to the proteins in mosquito saliva, which can hold many diverse pathogens, such as Malaria and Zika. This clinical study will assess the safety and immunogenicity of vaccine when given with or without adjuvant to small cohorts of healthy subjects. The vaccine may also contain a mosquito control element. The study will gather data on the mosquitoes’ fertility which feed on vaccinated volunteers.

Seemingly, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has earlier tested a previous version of AGS-v vaccine in a first-in-human trial. The trial was organized in NIAID’s Laboratory of Infectious Diseases’ Special Clinical Studies Unit at the NIH Clinical Center in Bethesda, Maryland. The final outcomes of this trial are expected in due course.

Trevor Phillips, Executive Chairman, hVIVO, has reportedly stated that the company is pleased to see the association with NIH and the University of Maryland School of Medicine remains as AGS-v PLUS, one of the assets in the joint venture Imutex, transfers into the clinic. The company is delighted that the asset development has been ongoing with NIAID-funded researchers analyzing the vaccine and extra funding for the trial by Innovate UK, he further added.

 

Source credit: https://imutex.com/wp-content/uploads/2019/07/AGS-v_PLUS_Phase_1_FINAL.pdf



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Walgreens and Kroger to form a new group purchasing venture
Walgreens and Kroger to form a new group purchasing venture
By Pankaj Singh

Walgreens, a renowned U.S. based pharmacy-led health, beauty and well-being company, and Kroger, an American retail company, reportedly announced that they would be expanding their existing relationship to create a new...

GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
By Pankaj Singh

 

  • The alliance is aimed at personalizing regenerative tissue manufacturing processes
  • Vascularized printed cells are set to pave the way for more complex biolog...

Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
By Pankaj Singh

Hummingbird Bioscience, an advanced biotherapeutics company, recently announced it has raised USD 19 million in a Series B funding round. Apparently, the financing round was co-led by GNTech Venture Capital and Mirae A...